Mikhail Blagosklonny: A Pioneer in the Fight Against Cancer

Rapamycin is a powerful drug used to treat cancer, lung disease, organ transplant rejection and as a coating for coronary stents. It is also known as Sirolimus and Rapamune. When the drug was first discovered in 1972 it was used as an anti-fungal agent until researchers realized it had amazing healing properties.

Mikhail Blagosklonny has done extensive research on cancer and its treatments. He is a professor of Oncology at Rosewell Park Institute located in Buffalo, New York. He is also the editor in chief at Oncotarget where he has published a tremendous amount of research on aging. He is a believer in the powers of Rapamycin and advocates its use to increase human longevity. His contributions to science are unmatched.

Rapamycin is the preferred drug to treat organ transplant rejection because it is less toxic towards the kidneys. It also can be used to prevent new kidneys from contracting the disease Hemolytic-Uremic Syndrome after a transplant. Research is still ongoing to see if this drug may one day be used to cure Alzheimer’s disease. Research also has shown signs in mice that Rapamycin could be used to treat Muscular Dystrophy in humans. The drug also treats cancer by promoting tumor regression and boosting the immune system towards the disease.

Mikhail Blagosklonny is focused on getting people around the world the best medical treatment regardless of their economic situation. He specializes his research on cancer and aging. In specific, he wants to figure out the link between cancer and aging and why the disease is more prevalent in older people. Mikhail Blagosklonny is highly respected as a researcher and professor and continues to inspire his peers and students. His goal is to not only find cancer treatments, but to treat the disease effectively and affordably without debilitating side effects.

His desire is to eliminate cancer cells without destroying critical healthy cells that are needed to recover after treatment. He hopes that his hard work against this disease will inspire future researchers to continue on his legacy in hopes of eradicating the disease. He truly wants quality cancer treatment to be affordable for everybody, not just the privileged.

He truly believes that this drug has the potential to increase human longevity, but more research still needs to be done. His test concluded that Rapamycin helped fight tuberculosis in mice. Research also showed that the immune system in elderly patients was improved when given the drug prior to the flu vaccine.